Explore Our Biomarker Menu

Biological or Clinical Significance:

Total iron-binding capacity (TIBC) or sometimes transferrin iron-binding capacity is a medical laboratory test that measures the blood’s capacity to bind iron with transferrin.[1] It is performed by drawing blood and measuring the maximum amount of iron that it can carry, which indirectly measures transferrin[2] since transferrin is the most dynamic carrier.

Taken together with serum iron and percent transferrin saturation clinicians usually perform this test when they are concerned about anemia, iron deficiency or iron deficiency anemia. However, because the liver produces transferrin, alterations in function (such as cirrhosis, hepatitis, or liver failure) must be considered when performing this test. It can also be an indirect test of liver function, but is rarely used for this purpose.

References:

Yamanishi H, Iyama S, Yamaguchi Y, Kanakura Y, Iwatani Y (January 2003). “Total iron-binding capacity calculated from serum transferrin concentration or serum iron concentration and unsaturated iron-binding capacity”. Clin. Chem. 49 (1): 175–8.

Harrison’s Principles of Internal Medicine. 17th Edition (2008). Pg. 2432 (Table 351-2)

Analyte:

TIBC

Matrix:

Status:

Experienced Running

Sensitivity-LLOQ:

Sensitivity-ULOQ:

platform

ELISA

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist






    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.